Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01076 ...
Drug Name Atorvastatin
Molecular Weight 558.6398
Molecular Formula C33H35FN2O5
CAS Number 134523-00-5
SMILES CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
External Links
DRUGBANK DB01076
T3DB T3D4980
PubChem Compound 60823
PDR 2338
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 6.36 - 6.36 - 'MSDS'
Boiling Point 722.0 ℃ 722 ℃ 'MSDS'
Melting Point 176.0 ℃ 176 ℃ 'MSDS'
pKa 4.46 - 4.46 - 'MSDS'

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
AUC 200.0 ng.h/ml 200.0 ng.h/ml PO, oral; DRUGBANK
Bioavailability 14.0 % 14 % PO, oral; DRUGBANK
Bioavailability 12.0 % 12.0 % PO, oral; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 28.0 ng/ml 28 ng/ml PO, oral; DRUGBANK
C Max 14.9 ngEq/ml 14.9±1.8 ngEq/ml PO, oral; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 1.5 h 1-2 h PO, oral; DRUGBANK
T Max 2.3 h 2.3±0.96 h PO, oral; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 37.5 L/h 625.0 ml/min Plasma clearance; DRUGBANK
Clearance 1.7 L/h/kg 29.0 ml/min/kg apparent clearance; at steady state; hydrolysis; PO, oral; normal,healthy; Male, men;  Female, women; adults; Elderly ↓ ;Hepatitis, Hep ↓ ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 380.0 L 380.0 L DRUGBANK
Volume of Distribution 5.4 L/kg ~5.4 L/kg at steady state; hydrolysis; PO, oral; normal,healthy; Male, men;  Female, women; adults; The Pharmacological Basis of Therapeutics
Half-life 14.0 h 14 h DRUGBANK
Half-life 30.0 h 30 h Metabolite; DRUGBANK
Half-life 19.5 h 19.5±9.6 h normal,healthy; adults; Male, men;  Female, women; Hepatic cirrhosis, cirr ↑ ; The Pharmacological Basis of Therapeutics
Eliminate Route 2.0 % <2 % Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 98.0 % >98 % plasma proteins; DRUGBANK
Protein Binding 98.0 % ≥98 % adults; normal,healthy; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 20.0 mg/day 20 mg/day PO, oral Lipitor atorvastatin calcium PDR
Max dose for children 10.0 mg/day 10 mg/day PO, oral Lipitor atorvastatin calcium PDR
Max dose for adolescents 20.0 mg/day 20 mg/day PO, oral Lipitor atorvastatin calcium PDR
Max dose for adults 80.0 mg/day 80 mg/day PO, oral Lipitor atorvastatin calcium PDR
Max dose for geriatric 80.0 mg/day 80 mg/day PO, oral Lipitor atorvastatin calcium PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1